ArticleMethods (San Diego, Calif.)2020
Pathway-based deep clustering for molecular subtyping of cancer.
Article in Methods (San Diego, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives.Cells · 2025Review
- Strategies to include prior knowledge in omics analysis with deep neural networks.Patterns (New York, N.Y.) · 2025Review
- Role of AI in empowering and redefining the oncology care landscape: perspective from a developing nation.Frontiers in digital health · 2025Review
- Prognostic heterogeneity of Ki67 in non-small cell lung cancer: A comprehensive reappraisal on immunohistochemistry and transcriptional data.Journal of cellular and molecular medicine · 2024Article
- Autosurv: interpretable deep learning framework for cancer survival analysis incorporating clinical and multi-omics data.NPJ precision oncology · 2024Article
- PAGER-scFGA: unveiling cell functions and molecular mechanisms in cell trajectories through single-cell functional genomics analysis.Frontiers in bioinformatics · 2024Article
- Risk stratification and pathway analysis based on graph neural network and interpretable algorithm.BMC bioinformatics · 2022Article
- Ten quick tips for biomarker discovery and validation analyses using machine learning.PLoS computational biology · 2022Article
- DEMA: a distance-bounded energy-field minimization algorithm to model and layout biomolecular networks with quantitative features.Bioinformatics (Oxford, England) · 2022Article
- Artificial intelligence and machine learning in precision and genomic medicine.Medical oncology (Northwood, London, England) · 2022Review
- PAGER Web APP: An Interactive, Online Gene Set and Network Interpretation Tool for Functional Genomics.Frontiers in genetics · 2022Article
- Artificial Intelligence for Precision Oncology.Advances in experimental medicine and biology · 2022Review
- A systematic comparison of data- and knowledge-driven approaches to disease subtype discovery.Briefings in bioinformatics · 2021Article
- Evaluation and comparison of multi-omics data integration methods for cancer subtyping.PLoS computational biology · 2021Article
- PathCNN: interpretable convolutional neural networks for survival prediction and pathway analysis applied to glioblastoma.Bioinformatics (Oxford, England) · 2021Article
- Machine learning analysis of TCGA cancer data.PeerJ. Computer science · 2021Article
- Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology.Frontiers in pharmacology · 2020Review
- Interpretable deep neural network for cancer survival analysis by integrating genomic and clinical data.BMC medical genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer is a genetic disease comprising multiple subtypes that have distinct molecular characteristics and clinical features. Cancer subtyping helps in improving personalized treatment and making decision, as different cancer subtypes respond differently to the treatment. The increasing availability of cancer related genomic data provides the opportunity to identify molecular subtypes. Several unsupervised machine learning techniques have been applied on molecular data of the tumor samples to identify cancer subtypes that are genetically and clinically distinct. However, most clustering methods often fail to efficiently cluster patients due to the challenges imposed by high-throughput genomic data and its non-linearity. In this paper, we propose a pathway-based deep clustering method (PACL) for molecular subtyping of cancer, which incorporates gene expression and biological pathway database to group patients into cancer subtypes. The main contribution of our model is to discover high-level representations of biological data by learning complex hierarchical and nonlinear effects of pathways. We compared the performance of our model with a number of benchmark clustering methods that recently have been proposed in cancer subtypes. We assessed the hypothesis that clusters (subtypes) may be associated to different survivals by logrank tests. PACL showed the lowest p-value of the logrank test against the benchmark methods. It demonstrates the patient groups clustered by PACL may correspond to subtypes which are significantly associated with distinct survival distributions. Moreover, PACL provides a solution to comprehensively identify subtypes and interpret the model in the biological pathway level. The open-source software of PACL in PyTorch is publicly available at https://github.com/tmallava/PACL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.